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Abstract
Objective The objective of this study is to evaluate the effectiveness of rfVIIa in reducing blood product requirements and
re-operation for postoperative bleeding after major abdominal surgery.
Background Hemorrhage is a significant complication after major gastrointestinal and abdominal surgery. Clinically
significant bleeding can lead to shock, transfusion of blood products, and re-operation. Recent reports suggest that activated
rfVIIa may be effective in correcting coagulopathy and decreasing the need for re-operation.
Methods This study was a retrospective review over a 4-year period of 17 consecutive bleeding postoperative patients who
received rfVIIa to control hemorrhage and avoid re-operation. Outcome measures were blood and clotting factor
transfusions, deaths, thromboembolic complications, and number of re-operations for bleeding.
Results Seventeen patients with postoperative hemorrhage following major abdominal gastrointestinal surgery (nine
pancreas, four sarcoma, two gastric, one carcinoid, and one fistula) were treated with rfVIIa. In these 17 patients, rfVIIa was
administered for 18 episodes of bleeding (dose 2,400-9,600 mcg, 29.8-100.8 mcg/kg). Transfusion requirement of pRBC
and FFP were each significantly less than pre-rfVIIa. Out of the 18 episodes, bleeding was controlled in 17 (94%) without
surgery, and only one patient returned to the operating room for hemorrhage. There were no deaths and two thrombotic
complications. Coagulopathy was corrected by rfVIIa from 1.37 to 0.96 (p<0.0001).
Conclusion Use of rfVIIa in resuscitation for hemorrhage after non-traumatic major abdominal and gastrointestinal surgery
can correct dilutional coagulopathy, reducing blood product requirements and need for re-operation.
Keywords Reoperation.Factor VII.Postoperative
complications.General surgery.Coagulopathy
Introduction
Activated factor VII (rfVIIa) plays a key role in hemostasis
by activating the extrinsic pathway of coagulation. Factor
VIIa initiates coagulation by interacting with exposed tissue
factor, in turn activating factor X to produce thrombin.
1
Thrombin then causes a conformational change of circulat-
ing platelets, and the activated surface of platelets further
activates the coagulation cascade to produce stable fibrin
clots.
2 Injured sub-endothelial cells express tissue factor.
Activation of factor VII by exposed tissue factor occurs at
sites of local tissue injury and endothelial damage, making
factor VII an attractive therapeutic agent for active
hemorrhage following surgical injury.
In 1999, the US Food and Drug administration approved
the use of recombinant rfVIIa for the treatment of the
inherited bleeding disorders hemophilia A and B as well as
inhibitors to factor VIII or IX. Because rfVIIa targets areas
of active bleeding, it has been used to treat non-
hemophiliac cases of coagulopathy or refractory hemor-
rhage in trauma, neurosurgery, cardiac surgery, and liver
transplantation.
3,4 In randomized, placebo-controlled trials
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5,6
Multiple case reports and case series have since suggested
the effectiveness of rfVIIa in treating hemorrhage during
surgery.
7–10
Although these studies have shown significant reduc-
tions in bleeding, there are no studies clearly evaluating the
role of rfVIIa in preventing re-operations for hemorrhage
following major abdominal gastrointestinal surgical proce-
dures. Although sepsis and anastamotic leaks are the most
common indications for re-operation following gastrointes-
tinal surgery, bleeding accounts for as much as18.5% of
urgent abdominal re-explorations.
11,12 Because these re-
operations represent additional trauma to the patient and
family and may result in increased morbidity and mortality,
surgeons are faced with the dilemma of continuing
potentially futile resuscitation with blood products or
performing a potentially harmful repeat operation. In
general, in these situations re-operation has been recom-
mended. However, we hypothesized that rfVIIa would
control bleeding by correcting dilutional coagulopathy after
surgery without significant complications. To evaluate the
role of rfVIIa in preventing re-operations for hemorrhage
following major abdominal and gastrointestinal surgery, we
performed a retrospective chart review of 17 consecutive
patients treated by a single surgeon with rfVIIa to avoid re-
operation.
Methods
This is a retrospective case series from a single surgeon in a
large tertiary referral medical center who prospectively
planned to first use rfVIIa (rather than return immediately
to the operating room) if significant bleeding occurred in
the postoperative setting following major gastrointestinal
and abdominal surgery. Postoperative patients were identi-
fied by surgical residents who notified the attending
surgeon that there was significant bleeding and may need
to return to the operating room (OR). Instead, each patient
received rfVIIa for attempted control of hemorrhage
without surgery. Inclusion criteria included patients with
bleeding less than 7 days from date of operation, 24-h blood
loss greater than 4 units packed red blood cells (pRBC),
and clinical evidence of hemorrhagic shock (systolic blood
pressure <100 mm Hg, pulse >100, and urine output
<400 cc/24 h). There was no threshold for Jackson-Pratt
drain output, but increasing output and frank blood instead
of serosanguinous output were considered by surgical
residents as evidence of postoperative hemorrhage. Exclu-
sion criteria included postoperative blood loss occurring
greater than 7 days from date of surgery and patients
receiving prophylactic or intraoperative rfVIIa. Patient
records from November 2004-November 2008 were
reviewed, and 17 patients who met these criteria were
identified.
The primary outcome was whether a patient needed
surgical re-exploration for hemorrhage within 3 days
following administration of rfVIIa. Secondary outcomes
included units of packed red blood cells, fresh frozen
plasma, cryoprecipitate, and platelets administered. Blood
components were calculated as total units in the 24-h period
prior to and following rfVIIa administration. Postoperative
blood loss was calculated by subtracting immediate
postoperative hematocrit by immediate pre-rfVIIa hemato-
crit. This should be considered as an approximation of
actual postoperative blood loss as peri-operative fluid shifts,
IV fluid administration, and variability in timing of lab
samples preclude definitive characterization of peri-
operative blood loss based on this calculation. Additionally,
mortality and thromboembolic complications following
administration of rfVIIa were assessed. Diagnostic criteria
for thromboembolic complications included diagnosis of a
lower extremity deep venous thrombosis by duplex ultra-
sound, hemorrhagic or embolic stroke on head CT, acute
myocardial infarction by EKG and serial troponin measure-
ment, and limb or mesenteric ischemia. Given the com-
plexity of operations contributing to the sample, we
included portal vein or SMV thrombosis diagnosed by CT
as thromboembolic complications.
P values reported for transfusion requirements, postop-
erative blood loss, and coagulopathy were calculated using
Wilcoxon rank sum tests. All statistical analyses were
performed using SAS 9.2 (SAS Institute, Cary, NC, USA).
This study did not require IRB review and approval
because data were extracted from the medical record in a
de-identified blinded fashion.
Results
Seventeen patients with postoperative hemorrhage follow-
ing major abdominal surgery were treated with activated
recombinant factor VII. Out of these 17 patients, nine cases
were due to pancreatic tumors requiring a Whipple
procedure or a distal pancreatectomy, four cases were due
to sarcomas requiring resection of the mass and involved
gastrointestinal structures, two cases were due to gastric
cancer requiring gastrectomy and Roux-en-Y gastrojeju-
nostomy, one case was due to goblet cell carcinoid
requiring a right hemicolectomy, and one case was due to
chylous ascites requiring laparotomy and ligation of the
cisterna chyli (Table 1). Average case length was 252 min.
Average estimated blood loss was 1.5 L, requiring 5.1±
0.8 L crystalloid,.8±0.2 L colloid, 3.5±1.6 units pRBC,
and 1.6±1.0 units fresh frozen plasma (FFP; Table 2). The
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may have contributed to postoperative dilutional coagulop-
athy as immediate postoperative hematocrit was 30.4±1.5.
In 16/17 patients, there was a single episode of bleeding
occurring within 7 days of the operation. One patient had
two episodes of bleeding in the defined post-operative
period; therefore, rfVIIa was administered for 18 episodes
of bleeding (doses 2,400-9,600 mcg, 29.8-100.8 mcg/kg).
The patient who had two episodes of bleeding was a 74-
year-old female undergoing Whipple pancreaticoduodenec-
tomy for an intraductal papillary mucinous tumor who had
bleeding on post-operative days 0 and 2. In all cases, there
was clinical evidence of hemorrhage necessitating resusci-
tation with blood component products and the possibility of
return to the OR. Postoperatively, average blood loss
resulted in a reduction of the hematocrit from a 30.4
postoperatively to 22.6 when the decision for rfVIIa was
made (Table 3). Post-rfVIIa hematocrit of 32.1 (p<
Table 1 Clinical Characteristics
Age Weight Diagnosis Primary procedure Thromboembolic
complications
Mortality Re-operation
for bleeding
32.00 66.6 Left flank Ewing’s
sarcoma
Resection of mass+hernia repair
with mesh and latissimus,
gluteal, and paraspinous muscle
flaps
No No Yes
74.00 94 IPMT Whipple No No No
52.00 52.3 Pancreatic cyst,
pancreatitis
Pancreatic neck dissection
with Roux-en-Y
pancreaticojejunostomy
No No No
56.00 92.7 Adenocarcinoma of the
duodenum, sigmoid
colon
Pancreaticoduodenectomy,
sigmoid resection with rectal
anastamosis. SMV injured
intraop and reconstructed.
Yes No No
69.00 69.1 Cystic mucinous
tumor
Distal pancreatectomy,
splenectomy
No No No
53.00 78.2 Intra-abdominal
liposarcoma
Resection of mass No No No
47.00 50 Left buttock neurofibroma
with AV malformation
and hematoma
Resection of mass No No No
49.00 72.7 Chylous ascites Laparotomy, ligation of
cisterna chyli
No No No
67.00 79.5 Serous cystadenoma
of pancreas
Distal pancreatectomy and
splenectomy
No No No
72.00 40.9 Gastric outlet obstruction
with afferent loop syndrome
Resection of Bilroth II
gastrojejunostomy with
new Roux-en-Y gastro
jejunostomy and jejunal
tube
No No No
85.00 76.4 Retroperitoneal liposarcoma Resection of mass, Left
hemicolectomy
No No No
76.00 49.9 Goblet cell carcinoid tumor
appendix, intraabdominal
abscess
Right hemicolectomy No No No
63.00 74 Pancreatic NET Pancreaticoduodenectomy
with SMA and SMV
reconstruction
Yes No No
71.00 47.6 Mucinous cystic neoplasm
pancreas
Pancreaticoduodenectomy No No No
76.00 56 IPMT Laparotomy, subtotal
pancreatectomy,
splenectomy, partial
gastrectomy, transverse
colectomy
No No No
78.00 57.2 Gastric cancer Total gastrectomy,
roux-en-y
No No No
88.00 50.8 Pancreatic cancer Distal pancreatectomy,
splenectomy, L nephrectomy
No No No
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was also a significant reduction in the INR (p<0.01).
In the 24 h pre-rfVIIa administration, a mean of 5.2 units
pRBCs, 2.0 units FFP, 33 units cryoprecipitate, and
0.39 units platelets were administered. Median values for
pRBC, FFP, cryoprecipitate, and platelets were 4, 1.5, 0, and
0, respectively. In the 24 h post-rfVIIa administration, a
mean of 0.83 units pRBC, 0.38 units FFP, 0 units Cryo, and
0.06 units platelets were given. Median values for all blood
products post-rfVIIa were 0 (Table 4). Transfusion of pRBC
and FFP was significantly less than pre-rfVIIa amount by
Wilcoxon rank sum test (p<0.00001 and p<0.01), and
transfusion of cryoprecipitate and platelets were not
significantly different (p=0.06 and p=0.09).
Out of the 18 episodes, bleeding was immediately
controlled in 17 (94%) without surgery. One patient
returned to the OR for surgical control of bleeding
(retroperitoneal hemorrhage following flank sarcoma resec-
tion and hernia repair). There were no deaths. There were
two thrombotic complications involving major veins, one
with thrombosis of the superior mesenteric vein and another
with thrombosis of the portal vein. Both of these veins had
been partially reconstructed during the surgical procedure.
Neither patient developed long-term complications from the
Table 2 Operative Characteristics
Patient Duration of
case (min)
Intraoperative
EBL
Intraoperative
crystalloid
Intraoperative
colloid
Intraoperative
pRBC
Intraoperative
FFP
ASA
class
Immediate
postoperative Hct
1 304 4,500 7,000 250 8 2 3 31.0
2 396 1,000 4,200 1,000 0 0 2 35.2
3 315 500 4,200 0 0 0 2 29.0
4 237 1,200 11,000 1,250 4 0 4 35.2
5 150 250 4,000 0 0 0 3 32.7
6 288 700 8,000 2,000 2 0 3 28.8
7 108 250 1,200 500 0 0 2 14.6.0
8 180 500 5,700 1,000 2 2 3 32.2
9 245 1,000 8,000 1,500 2 0 2 31.2
10 203 200 3,000 500 0 0 3 36.4
11 270 3,000 6,000 3,500 10 2 4 41.0
12 140 250 800 0 2 0 3 33.5
13 535 8,000 13,000 1,000 26 17 2 28.7
14 324 200 2,500 1,000 0 0 3 24.6
15 269 1,900 4,400 1,000 4 4 2 21.2
16 162 2,000 0 0 0 0 2 28.5
17 158 250 4,000 0 0 0 3 33.1
Median 245 700 4,200 1,000 2 0 3 31.2
Mean 252 1,512 5,118 853 3.5 1.6 3 30.4
Standard
error
25.9 495.4 845.0 220.8 1.6 1.0 0.2 1.5
Fluids are in milliliter. Blood components are in units transfused
ASA American Society of Anesthesiologist
Table 3 Postoperative Blood Loss and Coagulopathy Corrected by rfVIIa
Postop Blood Loss Pre-FVII Post-FVII p
Hematocrit −7.8 (−7) 22.6 (22.7) 32.1 (32.6) <0.00001
a
Platelets - 212 (188) 172 (142) 0.40
INR - 1.37 (1.4) 0.96 (0.9) <0.01
a
Units reported are mean and (median)
Unit for hematocrit is% of blood volume occupied by red blood cells. Unit for platelets is 10
3/uL
aStatistically significant
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myocardial infarction, or pulmonary embolism. The dose
of rfVIIa given ranged from 29.8 to 100.8 mcg/kg, with an
average of 78.0 mcg/kg. Bleeding was controlled in 8/18
episodes (44.4%) with the initial dose of rfVIIa, while 10/
18 (55.6%) bleeding episodes required two or more doses.
We subsequently routinely planned to give two doses
separated by 2 h, and in the latter half of the study period
(2006-2008), 7/9 (77.8%) bleeding episodes were treated
with two doses.
Discussion
Current dogma in surgery differentiates between surgical
and non-surgical causes of bleeding. As a cause of surgical
bleeding, postoperative hemorrhage has been traditionally
managed by re-operation. However, reoperation costs a
significant amount in money, time, energy, and potential
patient and family suffering. This study demonstrates the
ability of rfVIIa in conjunction with component resuscita-
tion to control hemorrhage and avoid reoperation for
bleeding following complex major abdominal and gastro-
intestinal surgery.
Postoperative hemorrhage following major abdominal
surgical procedures such as pancreatectomy and pancreato-
duodenectomy, the most common operations in our case
series, represent a challenging complication, with a mortal-
ity rate as high as 43%.
13 Likewise, for gastrointestinal
procedures such as gastrectomies, reoperation for postop-
erative bleeding has also been shown to be associated with
increased hospital length of stay as well as morbidity.
14 The
primary intervention for control of post-operative hemor-
rhage is ether transfusion of blood products or re-operation.
From a review of the literature, in 47.2-69% of cases blood
product transfusion alone was unable to cease hemorrhage,
necessitating urgent surgical re-exploration for hemostatic
control.
13,15–17 However, both surgical re-exploration and
excessive blood product replacement have been associated
with increased infection risk, multiorgan dysfunction,
increased hospital length of stay, and mortality.
11–13,18–20
More recently, interventional radiology has been used for
treatment of postoperative hemorrhage, but in terms of
hemostasis, morbidity, and mortality, it is comparable to
surgical re-exploration.
13 Therefore, reducing the amount of
blood products transfused and avoiding a re-operation
presents a real benefit to patents.
The administration of rfVIIa was effective in arresting
hemorrhage and preventing re-operation in 17/18 episodes
(94.4%). Further, it resulted in a reduction of blood
products transfused for all patients. Additionally, our results
show that rfVIIa administration was associated minimal
morbidity. Given that the average patient in our series had a
class 3 physical status by the American Society of
Anesthesiologist, reoperation would present increased risks.
Although there are many studies evaluating the use of
rfVIIa in the perioperative setting,
21,22 there are none that
evaluate the use of rfVIIa specifically in the postoperative
setting in major gastrointestinal and abdominal cases.
8,10
Most previous reports have focused on vascular and cardiac
surgery.
23–25 Because the current study excluded any
patient who received prophylactic and intra-operative
rfVIIa, we were able to assess the role of rfVIIa to prevent
re-operation in the postoperative setting for postoperative
hemorrhage, the primary outcome measurement of this
study. Administration of rfVIIa appeared to be an effective
therapy as it prevented re-operation in 94.4% of cases,
normalized coagulopathy, and raised the hematocrit. The
single case that returned to the OR for hemostatic control
involved a patient undergoing a complicated operation
involving resection of a large left flank Ewing’s sarcoma;
hernia repair with mesh; and latissimus, gluteal, and
paraspinous muscle flaps. In this patient, we wanted to
avoid a hematoma that would have compromised the
integrity of the hernia repair with mesh and flaps.
Administration of rfVIIa also significantly reduced blood
transfusion requirement for red blood cells, fresh frozen
plasma, cryoprecipitate, and platelets. This is a similar
finding to other studies that have evaluated the efficacy of
rfVIIa in controlling hemorrhage among trauma, cardiac,
vascular, and liver cases.
3,5,6,26,27 The average dose of
rfVIIa was 78.0 mcg/kg, and this is consistent with recent
studies showing efficacy of doses of rfVIIa >50 mcg/kg.
28
However, the wide range of dosing among various studies
occurs because of limited initial experience with the drug.
Eventually, the dose for rfVIIa was standardized to
>50 mcg/kg for two doses, and this was done in the last
ten patients.
Thrombosis is a potential complication of this drug.
Thrombosis of two major veins that had been reconstructed
24h pre-factor VIIa, mean (median) units 24h post-factor VII (median units) P value
pRBC 5.2 (4) 0.83 (0) <0.00001
a
FFP 2 (1.5) 0.38 (0) <0.01
a
Cryo 0.33 (0) 0 (0) =0.06
Platelet 0.39 (0) 0.06 (0) =0.09
Table 4 Transfusion Require-
ments pre- and post-rfVIIa
Administration
pRBC packed red blood cell,
FFP fresh frozen plasma,
Cryo cryoprecipitate
aStatistically significant
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complication of the procedure itself or to rfVIIa. However,
both patients stopped bleeding without reoperation and
neither patient had any long-term sequellae from the
thrombosis. There is a lack of consensus in the literature
regarding the association of rfVIIa with thromboembolic
complications with some studies concluding an increased
association
3 while others conclude no association.
7,28 In a
meta-analysis of rfVIIa used peri-operatively among
abdominal surgery patients, rfVIIa was not observed to
increase thromboembolic risk. Nevertheless, thromboembolic
complications should be considered, and the surgeon must
weigh the benefits of avoiding re-operation to the potential
risk of thromboembolism. Based on its efficacy and the
limited morbidity, we have continued to choose rfVIIa to
control postoperative bleeding and avoid re-operation.
Given the high cost of rfVIIa, other staff surgeons and
pharmacists have been cautious about its use. Using the
standard pharmacy Red Book reference and pharmacy
department at our institution, the price of rfVIIa is $1.08
per mcg, supplied in 1,200; 2,400; and 4,800 mcg vials. For
a 4,800-mcg dose (68.6 mcg/kg for a 70-kg patient), the
purchasing cost is $5,184. Patient charges at our institution
for 2 h of OR time is $17,640, aggregating anesthesia,
surgery, and OR time charges. Although a full cost-
effectiveness analysis was not undertaken as part of this
retrospective study, a basic cost analysis would suggest that
rfVIIa should be considered when surgical re-exploration is
the other alternative given the high cost of re-operation.
Further, we did not include the cost of continued transfu-
sion of blood and clotting factors that the use of rfVIIa
effectively reduced. Although this was not included in our
analysis, transfusion of blood products carry significant risk
for infections and increased length of stay, also arguing for
the use of rfVIIa to avoid reoperation. One cost-benefit
analysis has suggested that rfVIIa is only favorable if the
patient is expected to receive 40 units of RBC or one whole
blood transfusion (RBC, clotting factors, and platelets).
28
Loudon and Smith have proposed that rfVIIa is cost-
effective after transfusion of 14 units of RBC.
29 Including
the averted cost of re-operation, the cost of additional blood
products plus the cost of other related complications would
elucidate whether rfVIIa is potentially cost saving in the
setting of postoperative hemorrhage. Our results suggest
that a full cost-effectiveness analysis using decision analytic
models would provide important information for surgeons
and pharmacists when deciding to use rfVIIa.
Algorithms for the use of rfVIIa for postoperative
hemorrhage following non-traumatic major abdominal and
gastrointestinal surgery need to be developed. Clark and
colleagues defined three criteria for the administration of
rfVIIa: (1) transfusions of RBC to at least 1.5-fold the
blood volume (>15 units), (2) persistence of bleeding
despite conventional therapy, and (3) no foreseeable
immediate surgical bleeding control.
30 However, this
algorithm ignores the benefit posed by preventing the high
morbidities associated with surgical re-operation, which is
consistently recommended in the surgical literature. Instead,
Von Heymann and colleagues suggest that in situations of
persistent massive postoperative bleeding where the re-
maining options are only rfVIIa or surgical re-exploration, a
90 mcg/kg of rfVIIa should be given, repeated by another
dose one hour later if bleeding persists.
7 This algorithm
implies that successful treatment with rfVIIa must be
accompanied by correction of acidosis (pH>7.2), fibrin-
ogen (>100 mg/dL), platelets (>50,000/uL), and hemato-
crit (>24%), each of which may impact the efficacy of
rfVIIa.
31 We also have tried to correct these factors before
administering rfVIIa perhaps contributing to the effec-
tiveness of rfVIIa for preventing re-operation in our
experience.
Factor VII has been extensively studied among the
trauma surgery literature.
5,6,32 Additionally, the role of
increased FFP to PRBC ratio has also been examined in
massive transfusion protocols for civilian trauma.
33,34 A
massive transfusion protocol was implemented at our
institution in July 2005 supporting a 1:1.5 FFP/PRBC
ratio, improved communications, and enhanced systems
flow to optimize rapid blood product availability. Activa-
tion is recommended for greater than 4 units PRBCs
transfused in the first hour or expected transfusion require-
ments in excess of 10 units in a 12-h period. In our clinical
algorithm, factor VII is recommended for consideration if
there is persistent coagulopathy or hemorrhage after
administration of two massive transfusion packs or 12 units
pRBCS and 8 units of FFP.
Studies have shown that civilian trauma patients under-
going massive resuscitation often arrive with significant
dilutional coagulopathy from excessive crystalloid admin-
istration.
35 Likewise, the patients in our sample may have
also had significant dilutional coagulopathy as they
received a large amount of intraoperative crystalloid, with
a mean of 5.1 L resulting in mean immediate postoperative
hematocrit of 30.4. They received relatively few intra-
operative pRBC (3.5±1.6 units) and FFP (1.6±1.0 units)
given the large estimated blood loss (1,512±495.4 cc) for a
pRBC/FFP ratio of 2:2. Although the interpretation of these
data is challenged by the small sample size and large
standard error, these findings nevertheless highlight that the
patients in this sample could have had significant dilution
of clotting factors secondary to large intraoperative crystal-
loid and high pRBC relative to FFP transfusion. This may
be a common problem among patients undergoing complex
and long gastrointestinal and tumor resection surgical
procedures. This dilutional coagulopathy may explain the
success of rfVIIa in stopping bleeding in our patients.
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(MTP) among trauma patients at our institution has been
shown to improve mortality.
36 Given that the trauma
literature suggests improved outcomes with a 1:1 ratio of
FFP to pRBC, perhaps the need for rfVIIa could have been
averted had a 1:1 pRBC/FFP ratio been administered
instead of the ratio of 2:2 intra-operatively and 2:6 post-
operatively in this series. However, this is complicated by
data from our institution showing increased survival due to
decreased time to transfusion, as component ratios did not
change in the periods prior to and post-implementation of
the MTP.
36 Because our review extended to patients in
2004, five patients were resuscitated prior to the advent of
our institution’s massive transfusion protocol. Additionally,
the patients in this study did not meet our criteria for MTP,
since average blood loss in the 24-h period prior to rfVIIa
administration was 5.2 units pRBC. Therefore, for the
patients in our series, the amount and endpoints of
component resuscitation and rfVIIa occurred as a result of
direct decision making of the surgeon and not as a
consequence of the institutional MTP. This study suggests
the inadequacy of applying trauma resuscitation protocols
to patients undergoing major abdominal tumor resections as
patient characteristics such as age, type of operation, and
comorbidities clearly differ. Clinical decision-making algo-
rithms should be derived specifically for the setting of
postoperative bleeding and coagulopathy following non-
traumatic abdominal and gastrointestinal procedures.
Deficiencies of this study include small sample size
(n=17) and study design (retrospective case series).
Similar to previous studies of the use of rfVIIa among
surgical patients, a more robust case-control analysis was
not possible because of the heterogeneity of diagnoses
and operations.
8 An advantage of this study was that there
was no operator variability in surgical technique or
clinical decision making, since all patients were under
the care of one surgeon. In each instance if rfVIIa had not
been used, the attending surgeon deemed that the patient
would have needed to undergo surgical re-exploration.
Currently, there are no indications for the administration
rfVIIa for hemorrhage following major abdominal and
gastrointestinal surgery in the absence of inherited coagula-
tiondisorders.However,thisandother studies havesuggested
that rfVIIa reduces blood transfusion requirements, posing
both clinical and pharmaco-economic benefit. Additionally,
rfVIIa should be considered as an alternative to re-operation
for surgical control of bleeding in cases of postoperative
hemorrhage refractory to blood products. However, thrombo-
embolic complications may be a risk of this approach.
Randomized controlled studies and evaluations of
clinical algorithms are needed to provide a prospective
assessment of the role of rfVIIa in the common surgical
challenge of postoperative bleeding. This study highlights
that for patients undergoing long and complex gastrointes-
tinal surgical procedures, dilutional coagulopathy from
intraoperative resuscitation may be an under-recognized
condition that exacerbates postoperative bleeding. For this
subset of patients, rfVIIa in conjunction with traditional
blood component resuscitation can control bleeding and
decrease the probability of return to the OR in patients for
whom re-operation would pose significant risk of compli-
cations. However, given the small sample size and
limitations of this study, further research is warranted to
describe the subset of patients who would benefit most and
the cost-effectiveness of this approach.
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